Table 2.
Patient and treatment characteristics (n = 159)
| Number (%) or Median (IQR) | |
|---|---|
| Age (years) | 61 (Range, 47-80) |
| T stage | |
| pT2 | 48 (30%) |
| pT3a | 74 (47%) |
| pT3b | 29 (18%) |
| N stage | |
| pN0 | 128 (80%) |
| pN1 | 13 (8%) |
| pNx | 23 (15%) |
| Patholgic Gleason score | |
| 2-6 | 23 (15%) |
| 7 | 94 (59%) |
| 8-10 | 42 (26%) |
| Pre-radical prostatectomy prostate-specific antigen level (ng/mL) | 7 (5-12.3) |
| Radiation dose (Gy) | 66.6 (66-68.4) |
| Pelvic lymph node radiation therapy | 73 (46%) |
| Concurrent androgen deprivation therapy | 73 (46%) 4 (Range, 3-28) |
| Duration (mo) | |
| Follow-up time (mo) | 33 (18-59) |
IQR, interquartile range.